22 results about "Protamine" patented technology

The invention relates to a nanoparticle system for small intestine delivery, which is used for delivering exogenous miR-122-5p to the intestinal tract and comprises a miRNA-protamine compound inner core, a liposome middle layer wrapping the inner core and a p123 functional shell wrapping the liposome. Due to the adoption of the technical scheme, a nano-targeting delivery technology is combined with paternal epigenetic programming intervention for the first time, and a brand-new nano-drug treatment thought is provided for intergenerational genetic diseases caused by exposure of environmental adverse factors. By delivering exogenous miR-122-5p to the intestinal tract, the miRNA spectrum unbalanced due to exposure of paternal BaP can be directly improved.

The invention discloses a coregonus peled protamine peptide enzymolysis device and method, and belongs to the technical field of coregonus peled protamine peptide enzymolysis, and the coregonus peled protamine peptide enzymolysis method comprises the steps of pretreatment, ultrasonic-assisted acid extraction, precipitation and composite purification, and multistage impurity removal and refining. The target protein is promoted to be fully dissolved out; the coregonus peled protamine peptide enzymolysis device is composed of a supporting mechanism, a stirring mechanism, a first adjusting mechanism, a second adjusting mechanism and a switching mechanism. The supporting mechanism is matched with various stirring barrels through external threaded pipes of different specifications. The first adjusting mechanism adjusts the immersion position of the stirring blade by means of bevel gear transmission, and the deep vortex and cavitation effect are avoided; the second adjusting mechanism drives a screw rod through a gear to adjust the distance between the stirring blades and the barrel wall, and a stirring dead zone is eliminated; the switching mechanism completes vacuum degassing and nitrogen filling through a three-way switching valve, foam is inhibited, and sample oxidation is prevented.

The present invention belongs to the field of molecular biology and genetics, and in particular relates to a method for editing a bovine gene based on Pro-iCHI. The present invention provides a method for editing a bovine gene based on Pro-iCHI. Protamine is transiently expressed in gene-edited b-haSCs, which are then injected to mature oocytes to obtain reconstructed embryos. Protamine can eliminate abnormal DNA methylation resulting from oocyte intracytoplasmic haSCs injection and enable the nucli to compress into sperm-like structures, and the obtained bovine Pro-iCHI embryos can successfully develop into blastocysts, with a blastocyst rate comparable to that of the embryos obtained by in vitro fertilization. Moreover, in the present invention, a protamine-encoding gene is inserted into a Saccharomyces cerevisiae protein expression vector for transient expression, which ensures that abnormal DNA methylation is erased, without integration into the genome resulting in the insertion of exogenous genes.

The invention belongs to the technical field of biological medicine, and particularly relates to a heparin small molecule antagonist-quaternary ammonium salt macrocyclic compound and a preparation method thereof. The quaternary ammonium salt macrocyclic compound disclosed by the invention comprises three piperazine functionalized quaternary ammonium salt macrorings and four methylated quaternary ammonium salt macrorings; the quaternary ammonium salt macrocyclic compound can be used for preparing a heparin small molecule antagonist. The compound shows excellent antagonism efficiency on ungraded heparin and low-molecular-weight heparin, and shows a wide therapeutic dose window; and the antagonism efficiency and dosage window of the protamine are superior to those of clinically used protamine. Besides, in-vivo and in-vitro safety evaluation proves that the quaternary ammonium salt macrocycle has good biocompatibility, and shows clinical transformation potential as a protamine substitute as a small molecule antagonist.

This invention relates to protamine molecules. More specifically, this invention relates to protamine molecules and their use in the delivery of payload molecules.

The invention discloses a protamine mediated fluorescence resonance energy transfer (FRET) sensing system and application thereof. According to the protamine, a tetraphenylethylene-derived anionic molecule (4, 4 '-(((1, 2-stilbene-1, 2-disubunit) bis (4, 1-phenyl)) bis (aza-disubunit)) bis (4-sodium oxobutyrate)) is electrostatically enriched on the surface of the protamine, and a tetraphenylethylene group emits fluorescence after being aggregated and acts as an energy donor; furthermore, cationic dye (4-(4-dimethylaminostyryl)-1-methyl iodide pyridine) is added as an energy receptor, and a fluorescence resonance energy transfer (FRET) system is constructed. Through construction of the FRET system, long-wavelength fluorescence emission can be obtained, high-sensitivity detection of trypsin and screening of enzyme preparations are achieved, and the FRET system is expected to be applied to complex media.

The invention relates to a hypertension implant rod and a preparation method thereof, and relates to the technical field of hypertension implant rods, the hypertension implant rod comprises a quick release layer, a slow release layer and a long-acting regulation and control layer from outside to inside, the quick release layer comprises, by mass, 60-70% of bacterial cellulose (BC), 15-25% of polydopamine (PDA), 3-8% of ciprofloxacin, 3-8% of protamine and 4-6% of indapamide, the slow release layer comprises, by mass, 20-30% of a long-acting regulation and control layer, and the long-acting regulation and control layer comprises, by mass, 20-30% of a slow release layer and 20-30% of a long-acting regulation and control layer. The sustained release layer is prepared from 55 to 65 percent of polylactic acid-glycolic acid copolymer, 20 to 30 percent of cross-linked gelatin, 8 to 12 percent of lacidipine and 4 to 6 percent of spirolactone, and the long-acting regulation and control layer is prepared from 65 to 75 percent of L-polylactic acid, 20 to 30 percent of beta-glycine crystal, 3 to 5 percent of silk fibroin (SF), 0.5 to 1.0 percent of calcitonin gene related peptide CGRP and 0.1 to 0.3 percent of neuropeptide Y. The hypertension implant rod can be matched with various treatment cycles through gradient degradation, realizes'on-demand treatment ', is high in biocompatibility, is suitable for subcutaneous implantation, and is convenient and safe to operate.

The present invention relates to a lipid nanoparticle-based drug delivery system using recombinant protamine and a method for preparing same. The lipid nanoparticle-based drug delivery system of the present invention can stably deliver a gene to a target cell in vivo by using a recombinant protamine protein having excellent stability when forming a complex with an anionic gene. In addition, the lipid nanoparticle-based drug delivery system can improve the expression level of the gene in the target cell, and thus can be effectively used in related technical fields such as lipid nanoparticle-mediated gene therapy.

The invention discloses a cationic fluorescent probe with long wavelength emission as well as a preparation method and application of the cationic fluorescent probe. The fluorescent probe disclosed by the invention has the characteristic of emitting red fluorescence, the probe is combined with heparin through electrostatic interaction, and the fluorescence is quenched, so that the heparin is detected; furthermore, the protamine is specifically combined with the heparin, probe molecules are released, fluorescence is recovered, and the protamine is detected; the long-wavelength fluorescent probe provided by the invention has good selectivity and sensitivity on heparin and protamine, and can be applied to a serum dilution environment.

The invention relates to the technical field of heparin and protamine analysis, in particular to a method for determining the dosage of heparin and protamine. The method comprises the steps that a first sample set A is obtained, Ai is the ith first sample, and Ai is obtained by adding different doses of preset chemical substances into a blood sample of a target individual; acquiring a whole blood activation blood coagulation time detection result set B; obtaining a target model according to the whole blood activation coagulation time detection result in the step B, the dosage of the corresponding added preset chemical substance and the preset model; and according to the target whole blood activated coagulation time and the target model, obtaining the dosage of a preset chemical substance corresponding to the target whole blood activated coagulation time of the target individual. According to the method, the heparin dosage and the protamine dosage which are suitable for the target individual and correspond to the target whole blood activation coagulation time can be determined, and reference is provided for the heparin dosage and the protamine dosage in an actual application scene.

A method of erasing an abnormal epigenetic modification in a sheep iCHI embryo and use thereof. A method including the steps of: transferring a recombinant plasmid expressing protamine into a sheep androgenetic haploid embryonic stem cell, then introducing the cell into a mature sheep oocyte, and performing activation and culture to obtain a sheep iCHI embryo without abnormal epigenetic modifications. In the present disclosure, abnormal methylations in iCHI embryos may be erased by transient expression of protamine in o-haSCs. The blastocyst rate of the prepared Pro-iCHI embryos is significantly higher than that of iCHI embryos, and is similar to that of IVF embryos. The resulting embryos can be used for embryo transfer to obtain semi-cloned gene-edited sheep, providing materials for subsequent breeding applications.

This invention provides an impregnated paper with anti-mildew, antibacterial, and antiviral properties, and its preparation process. The impregnated paper comprises the following raw materials by percentage: 0.8-1.4% plant extract, 45-57% film-forming resin, 1-1.5% calcium peroxide, 1-1.5% protamine, 0.5-0.8% capsid protein, 0.3-0.5% oligosaccharide chain protein, 3-4% nano-sepiolite, 0.8-1.2% calcium hypochlorite, 0.1-0.2% silver-loaded nanoparticles, 6-8% slow-release carrier, 0.6-0.8% photoinitiator, 0.3-0.5% surfactant, 3-4% plasticizer, 0.1-0.2% curing agent, 0.2-0.3% dispersant, 0.2-0.4% crosslinking agent, 0.2-0.3% moisture-proof agent, 0.2-0.4% antioxidant, 0.1-0.3% antistatic agent, and the balance being solvent. The combined effect of the components in this invention enables the impregnated film paper to possess excellent comprehensive properties such as mildew resistance, antibacterial properties, and antiviral properties, reducing the probability of bacterial and viral transmission and improving the practicality and safety of the impregnated film paper in decorative panels for underfloor heating environments, humid areas (such as bathroom cabinets), or medical facilities.

The application relates to the technical field of heparin and protamine analysis, in particular to a heparin and protamine dose determination method. The method comprises the following steps: obtaining a first sample set A, wherein A i is the ith first sample, A i is obtained by adding different doses of a preset chemical substance in a blood sample of a target individual; obtaining a whole blood activated coagulation time detection result set B; obtaining a target model according to the whole blood activated coagulation time detection result in B, the dose of the corresponding added preset chemical substance and a preset model; and obtaining the dose of the preset chemical substance corresponding to the target whole blood activated coagulation time of the target individual according to the target whole blood activated coagulation time and the target model. The application can determine the heparin dose and the protamine dose suitable for the target individual and corresponding to the target whole blood activated coagulation time, and provides a reference for the heparin dose and the protamine dose in an actual application scene.

The application discloses a kind of nano-carriers for co-loading PD-1 antibody and catalase. Specifically, the nano-carriers contain: 30~60 wt% neutral phospholipid, 20~50 wt% anionic phospholipid, 1~20 wt% apolipoprotein and / or its mimetic peptide, 0.1~10 wt% protamine, 0.01~5 wt% hyaluronic acid, 1~10 wt% aPD-1 antibody and 1~10 wt% catalase, based on the total weight of the nano-carriers being 100 wt%. The nano-carriers of the application can synergistically enhance the therapeutic effect on breast cancer by co-encapsulating PD-1 antibody and catalase.

The invention relates to the technical field of biological medicine, and particularly discloses a monoclonal antibody resisting DNA methyltransferase 3A (DNMT3A) and application of the monoclonal antibody in osteoarthritis treatment. The antibody is a single-chain antibody scFv-A7 and is obtained by screening through a phage display technology, a complementary determining region (CDR) of a heavy chain variable region (VH) of the antibody comprises sequences shown in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, a CDR of a light chain variable region (VL) of the antibody comprises sequences shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, and a full-length sequence of the antibody is SEQ ID NO: 7. The antibody has high affinity, and the binding EC50 value of the antibody and DNMT3A protein is 5.2 nM. In an osteoarthritis mouse model, after the antibody and protamine form nano-particles, the nano-particles can be effectively delivered into a cell nucleus, the activity and expression of DNMT3A are inhibited, the levels of serum inflammatory factors IL-1beta and IL-6 are reduced, and the joint function score is improved. The invention provides a novel treatment strategy of targeted epigenetic regulation for osteoarthritis, and overcomes the problem of poor selectivity of the existing small-molecule inhibitor.

The present invention provides a more effective use of protamine or a protamine degradation product. Provided is a composition for anti-biofilm and / or anti-microbial use, the composition comprising at least two components selected from protamine, protamine degradation products, basic polyamino acids (e.g., polylysine, polyornithine, and polyarginine), and salts thereof. Also provided is a composition for inhibiting production of an extracellular polysaccharide (EPS), the composition containing a protamine degradation product or a salt thereof.

The invention discloses a stabilizer for a recombinant animal interferon-alpha liquid preparation and application of the stabilizer, and belongs to the field of biomedicine. The stabilizer is composed of protamine and sodium glycinate. Experiments show that protamine and sodium glycinate are combined for use, so that a remarkable synergistic interaction effect is achieved, and the degradation and inactivation of recombinant protein in a liquid environment can be effectively inhibited. After the stabilizer is added, the storage life of the recombinant duck interferon-alpha under the condition of 4 DEG C is greatly prolonged from less than 3 months to 18 months or more, and the stabilizer has an excellent protection effect on chicken-source and pig-source interferon and interleukin fusion protein. The recombinant animal interferon liquid preparation is simple in component, low in cost and high in safety, solves the bottleneck problem that the recombinant animal interferon liquid preparation is difficult to store for a long time, and has a wide industrialization prospect.

The invention discloses preparation and application of a gold cluster compound of a non-viral targeted in-vivo gene delivery vector, and relates to the field of application of non-viral gene delivery vectors. Au and a specific ligand protamine and Ang-2 peptide have a synergistic effect to form a cluster compound, and the molar ratio of Au to Pro to Ang-2 is 17: 25: (10-40), preferably 17: 25: 34. Mixing the gold salt solution with the ligand to form a mixed solution; under the conditions of certain temperature and pH, the mixed solution system is subjected to a reduction reaction, high-valence Au ions in the gold salt are reduced into Au atoms or monovalent Au ions, and Au forms a gold cluster compound through physical or chemical interaction; the sulfydryl-containing ligand is polypeptide or protein with better biocompatibility, and the cluster compound disclosed by the invention can be used for successfully delivering nucleic acid into cells and has good biocompatibility.

The invention provides a polyarginine protamine antibacterial peptide as well as a preparation method and application thereof, and belongs to the technical field of active peptide preparation. The polypeptide provided by the invention is separated and identified from sturgeon protamine, and the sequence rule and antibacterial activity of the separated target derived peptide are determined through amino acid sequence identification and in-vitro bacterial experiments. The polyarginine type cationic antibacterial peptide provided by the invention is prepared through acid extraction, alcohol precipitation, molecular sieve chromatography and cation exchange chromatography technologies, and in-vitro bacteriostasis experiments prove that the polyarginine type cationic antibacterial peptide can play a remarkable role in inhibiting and killing various bacteria including salmonella pullorum. The raw materials adopted by the invention are natural, high in safety and biocompatibility, and suitable for development of antibiotic substitute products and related drugs thereof.

A nanoparticle drug based on a small interfering RNA (siRNA) targeting JFK and use thereof are provided. Nucleotide sequences of the sense strand and the antisense strand of the siRNA targeting JFK are set forth in SEQ ID NO: 1 and SEQ ID NO: 2, respectively. Liposomes can be used to encapsulate the complex of the siRNA and a protamine to produce a nanoparticle drug targeting JFK, which may be used to treat a disease related to abnormally-high expression of JFK. In this disclosure, breast cancer 4T1 cell-based tumor-bearing mice serve as the model for evaluating the anti-tumor activity of combined therapy involving the nanoparticle drug targeting JFK and radiotherapy. The results reveal that this combined therapy exhibits superior anti-tumor activity compared to the control group.

The application discloses a kind of melatonin nanoparticles and preparation method and purposes thereof.The nanoparticles are composed of melatonin, bilirubin and protamine, and the mass ratio of melatonin, bilirubin and protamine is 3:(1-5):(1-10).The preparation method comprises first preparing a mixed solution of melatonin and bilirubin, then slowly dropping the mixed solution into a protamine solution, removing organic solvent after ultrasonic treatment, and freeze-drying to obtain melatonin nanoparticles.The prepared melatonin nanoparticles are simple to prepare, have high drug loading capacity and good stability, can significantly improve embryo implantation rate, pregnancy rate and birth rate by improving local microenvironment after co-transplantation with embryos, exhibit significant embryo protection effect, and have good clinical application prospect.

The application discloses a protamine-chitosan compound and a preparation method and application thereof, and relates to the technical field of biological resource utilization and wastewater treatment. 60 After Co irradiation and compounding, the protamine-chitosan compound is freeze-dried, and can be used as a flocculant for removing arsenic from wastewater. The flocculant is environment-friendly, the arsenic removal process is simple, the arsenic removal efficiency is high, the flocculant has a certain desorption capacity, can be reused, and cost reduction is achieved.